ICML 2025 | Results from Atalanta-1: GLPG5101 in patients with R/R NHL

It was really a pleasure to present the data from the Atalanta-1 trial cohort 3 which we included patients with indolent non-Hodgkin lymphoma and they were treated with GLPG5101 which is a CD19 CAR T-cell therapy. So we screened 39 patients and subsequently we had 34 patients which were leukapheresed and started chemotherapy, lymphodepleting chemotherapy. So there were 32 patients who were infused with CAR T-cells. The majority of the patients had fresh CAR T-cells. This is quite unique of this product because it has an option to have a vein-to-vein time of only 7 days. So in the majority of the patients that was possible and they had a fresh CAR T-cell product. We included patients with high-risk disease. They were also heavily pre-treated and the outcomes were really good. So only one patient with follicular lymphoma, so we had 27 patients with follicular lymphoma and five patients with marginal zone lymphoma. And only one patient with follicular lymphoma did not respond, but all others responded. So the overall response rate was 97%. And the responses were also durable. So we have now a follow-up time of 12.3 months and all patients who responded are still in complete remission. And we also did some MRD testing for the patients who are in complete remission. And of the ones we tested, they were all MRD negative. So that’s quite good. So the toxicities, we mainly saw grade 3 toxicities of hematological origin. We didn’t see any grade 3 infections, no deaths. And for CRS and ICANS, one third had CRS, any grade CRS, but no grade 3 CRS was seen. And ICANS, we had 13% of ICANS, any grade ICANS, and one patient with grade 3 ICANS. So that was like a favorable toxicity profile. So we are really enthusiastic about this outcome in this group of patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.